Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:07:24.147Z.
Consensus retrieved: 2026-10-06T13:40:36.500Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:07:24.147Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 985de651f734d9a38a22cd49a3876f31e599b575395053e6524d1a54e91db9a8
Forward PE Ratio (N/A) = Dated Quote Price ($8.61) / Consensus Forward EPS ($-7.23)
FORWARD PE RATIO
N/A
Lyell Immunopharma, Inc.
Market Cap
$210.98M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $210.98M | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 18.65 |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 21.01 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $8.61, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-7.24 | $-7.50 – $-6.98 | 4 | n/m |
| 2027-12-31 | $-7.59 | $-10.28 – $-5.51 | 4 | n/m |
| 2028-12-31 | $-6.26 | $-7.61 – $-5.15 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
